To explore the efficacy and safety of a small-volume-plasma artificial liver support system (ALSS) in the treatment of acute-on-chronic liver failure (ACLF). A retrospective analysis was performed. All ACLF patients received ALSS of plasma exchange & double plasma molecular absorb system (PE+DPMAS) treatment, and successfully completed this treatment. Patients were divided into small-volume and half-volume plasma groups. We compared the changes of the indicators on liver function, kidney function, blood coagulation function, and blood ammonia level before and after PE+DPMAS treatment; we compared the short-term and long-term curative effects between small-volume and half-volume plasma groups; and the factors influencing Week 4 and Week 12 mortality of ACLF patients were analyzed. The Week 4 improvement rates were 63.96 % and 66.86 % in the small-volume and half-volume plasma groups, respectively. The Week 12 survival rates in the small-volume-plasma and half-volume plasma groups were 66.72 % and 64.61 %, respectively. We found several risk factors affecting Week 4 and Week 12 mortality. Kaplan-Meier survival curves suggested no significant difference in Week 4 and Week 12 survival rates between the small-volume and half-volume plasma groups (P=0.34). The small-volume-plasma PE+DPMAS treatment could effectively reduce bilirubin and bile acids, and this was an approach with high safety and few complications, similar to the half-volume-plasma PE+DPMAS treatment. The small-volume-plasma PE+DPMAS has the advantage of greatly reducing the need for intraoperative plasma, which is especially of importance in times of shortage of plasma.

The 1st Affiliated Hospital of Kunming Medical University Yunnan Kunming China

See more in PubMed

Zhang J, Luo H, Han Y, Zhou X. Sequential versus mono double plasma molecular adsorption system in acute-on-chronic liver failures: A propensity-score matched study. Int J Artif Organs. 2021;12:391398820987565. doi: 10.1177/0391398820987565. PubMed DOI

Diagnostic and treatment guidelines for liver failure (in Chinese) Zhonghua ganzangbing zazhi (Chinese Journal of Hepatology) 2013;21:177–183. PubMed

Gu WY, Xu BY, Zheng X, Chen J, Wang XB, Huang Y, et al. Acute-on-chronic liver failure in China: rationale for developing a patient registry and baseline characteristics. Am J Epidemiol. 2018;187:1829–1839. doi: 10.1093/aje/kwy083. PubMed DOI

Bernal W, Jalan R, Quaglia A, Simpson K, Wendon J, Burroughs A. Acute-on-chronic liver failure. Lancet (London, England) 2015;386:1576–1587. doi: 10.1016/S0140-6736(15)00309-8. PubMed DOI

Qin G, Shao JG, Zhu YC, Xu AD, Yao JH, Wang XL, et al. Population-representative Incidence of Acute-On-Chronic Liver Failure: A Prospective Cross-Sectional Study. J Clin Gastroenterol. 2016;50:670–675. doi: 10.1097/MCG.0000000000000538. PubMed DOI PMC

Thuluvath PJ, Thuluvath AJ, Hanish S, Savva Y. Liver transplantation in patients with multiple organ failures: Feasibility and outcomes. J Hepatol. 2018;69:1047–1056. doi: 10.1016/j.jhep.2018.07.007. PubMed DOI

Arulraj R, Neuberger J. Liver transplantation: filling the gap between supply and demand. Clin Med (Lond) 2011;11:194–198. doi: 10.7861/clinmedicine.11-2-194. PubMed DOI PMC

Finkenstedt A, Nachbaur K, Zoller H, Joannidis M, Pratschke J, Graziadei IW, et al. Acute-on-chronic liver failure: excellent outcomes after liver transplantation but high mortality on the wait list. Liver Transpl. 2013;19:879–886. doi: 10.1002/lt.23678. PubMed DOI

Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology (Baltimore, Md) 2015;62:243–252. doi: 10.1002/hep.27849. PubMed DOI

Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut. 2017;66:541–553. doi: 10.1136/gutjnl-2016-312670. PubMed DOI PMC

EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69:154–181. doi: 10.1016/j.jhep.2018.03.018. PubMed DOI

Im GY, Cameron AM, Lucey MR. Liver transplantation for alcoholic hepatitis. J Hepatol. 2019;70:328–334. doi: 10.1016/j.jhep.2018.11.007. PubMed DOI

Pless G. Artificial and bioartificial liver support. Organogenesis. 2007;3:20–24. doi: 10.4161/org.3.1.3635. PubMed DOI PMC

Selden C, Bundy J, Erro E, Puschmann E, Miller M, Kahn D, et al. A clinical-scale BioArtificial Liver, developed for GMP, improved clinical parameters of liver function in porcine liver failure. Sci Rep. 2017;7:14518. doi: 10.1038/s41598-017-15021-4. PubMed DOI PMC

García Martínez JJ, Bendjelid K. Artificial liver support systems: what is new over the last decade? Ann Intensive Care. 2018;8:109. doi: 10.1186/s13613-018-0453-z. PubMed DOI PMC

Qin G, Shao JG, Wang B, Shen Y, Zheng J, Liu XJ, et al. Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience. Medicine. 2014;93:e338. doi: 10.1097/MD.0000000000000338. PubMed DOI PMC

Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol. 2016;64:69–78. doi: 10.1016/j.jhep.2015.08.018. PubMed DOI

Shen Y, Wang XL, Wang B, Shao JG, Liu YM, Qin Y, et al. Survival Benefits With Artificial Liver Support System for Acute-on-Chronic Liver Failure: A Time Series-Based Meta-Analysis. Medicine. 2016;95:e2506. doi: 10.1097/MD.0000000000002506. PubMed DOI PMC

Alshamsi F, Alshammari K, Belley-Cote E, Dionne J, Albrahim T, Albudoor B, et al. Extracorporeal liver support in patients with liver failure: a systematic review and meta-analysis of randomized trials. Intensive Care Med. 2020;46:1–16. doi: 10.1007/s00134-019-05783-y. PubMed DOI

Vaid A, Chweich H, Balk EM, Jaber BL. Molecular adsorbent recirculating system as artificial support therapy for liver failure: a meta-analysis. ASAIO J. 2012;58:51–59. doi: 10.1097/MAT.0b013e31823fd077. PubMed DOI

Pironi L, Arends J, Bozzetti F, Cuerda C, Gillanders L, Jeppesen PB, et al. ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr. 2016;35:247–307. doi: 10.1016/j.clnu.2016.01.020. PubMed DOI

Li S, Chen Y. [Coping with shortage of plasma-The new therapeutic pattern of non-bioartificial liver] Clin Hepatol. 2017;33:1687–1692.

Guideline for diagnosis and treatment of liver failure (in Chinese) Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 2019;27:18–26. PubMed

Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171–354. doi: 10.1002/jca.21705. PubMed DOI

Li S, Chen Y. Coping with shortage of plasma-The new therapeutic pattern of non-bioartificial liver. J Clin Hepatol. 2017;33:1687–1692.

Li S, Wang L, Wu B, Zhu L, Duan M, Chen Z. [Clinical observation of dual plasma adsorption combined with plasma exchange in the treatment of severe hepatitis B] Clinical Meta. 2015;30:781–784.

Guo X, Wu F, Guo W, Zhang J, Yang Y, Lu Y, et al. Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure. J Int Med Res. 2020;48:300060520932053. doi: 10.1177/0300060520932053. PubMed DOI PMC

Zhang J, Wan H, Duan Z, Su G, Han D, Li Y, et al. Establishment and application of plasma exchange mathematical model (in Chinese) Shandong Med. 2007;(19):35–37.

Cheng Z, Sun G, Lin H, Lu Y, Zhou Y, Wen A. Meta-analysis of the clinical efficacy and safety of plasma exchange in the treatment of liver failure (in Chinese) Chin J Evid-Based Med. 2015;15:664–671.

Zhong S, Wang N, Zhao J, Zhang L, Luo L, Zeng W, et al. Plasma exchange combined with dual plasma adsorption therapy improves the prognosis of chronic acute liver failure (in Chinese) Chin J Hepatol. 2018;26:744–749. PubMed

Yao J, Li S, Zhou L, Luo L, Yuan L, Duan Z, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure. J Clin Apher. 2019;34:392–398. doi: 10.1002/jca.21690. PubMed DOI PMC

Li S, Liu J, Chen Y. Non-bioartificial liver in liver failure: Clinical application and research advances. J Clin Hepatol. 2019;35:1909–1915.

Liu X, Xin S, Chen J, Xiao L, Yang H, Tong J, et al. Significance of liver failure staging in predicting the prognosis of HBV-acute-on-chronic liver failure. Acad J Chin Pla Med Sch. 2014;35:521–524+44.

Tian X, Peng Y, Wu S, Wu G. Liver failure staging and MELD predicted the short term prognosis of HBV-acute-on-chronic liver failure. Chongqing Med. 2017;46:1079–1081.

Chen T, Yang Z, Choudhury AK, Al Mahtab M, Li J, Chen Y, et al. Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region. Hepatol Int. 2019;13:695–705. doi: 10.1007/s12072-019-09992-x. PubMed DOI

Hernaez R, Kramer JR, Liu Y, Tansel A, Natarajan Y, Hussain KB, et al. Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. J Hepatol. 2019;70:639–647. doi: 10.1016/j.jhep.2018.12.018. PubMed DOI

Liu J, Liang W, Jing W, Liu M. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ. 2019;97:230–238. doi: 10.2471/BLT.18.219469. PubMed DOI PMC

Liu XY, Hu JH, Wang HF, Chen JM. [Etiological analysis of 1977 patients with acute liver failure, subacute liver failure and acute-on-chronic liver failure] Zhonghua Gan Zang Bing Za Zhi. 2008;16:772–775. Chinese. PubMed

Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014;60:2099–2108. doi: 10.1002/hep.27406. PubMed DOI PMC

Liu H, Zhang Q, Liu L, Cao Y, Ye Q, Liu F, et al. Effect of artificial liver support system on short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Artif Organs. 2020;44:E434–e447. doi: 10.1111/aor.13710. PubMed DOI

Du L, Ma Y, Zhou S, Chen F, Xu Y, Wang M, et al. A prognostic score for patients with acute-on-chronic liver failure treated with plasma exchange-centered artificial liver support system. Sci Rep. 2021;11:1469. doi: 10.1038/s41598-021-81019-8. PubMed DOI PMC

Mu X, Tong J, Xu X, Chen J, Su H, Liu X, et al. World Gastroenterology Organisation classification and a new type-based prognostic model for hepatitis B virus-related acute-on-chronic liver failure. Clin Res Hepatol Gastroenterol. 2021;45:101548. doi: 10.1016/j.clinre.2020.09.009. PubMed DOI

Yu Z, Zhang Y, Cao Y, Xu M, You S, Chen Y, et al. A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators. Sci Rep. 2021;11:1810. doi: 10.1038/s41598-021-81431-0. PubMed DOI PMC

Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470. doi: 10.1053/jhep.2001.22172. PubMed DOI

Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130:1652–1660. doi: 10.1053/j.gastro.2006.02.010. PubMed DOI

Liu H, Zhang H, Wan G, Sang Y, Chang Y, Wang X, et al. Neutrophil-lymphocyte ratio: a novel predictor for short-term prognosis in acute-on-chronic hepatitis B liver failure. J Viral Hepat. 2014;21:499–507. doi: 10.1111/jvh.12160. PubMed DOI

Xu X, Chen W, Zhang L, Miao R, Zhou Y, Wan Y, et al. Prognostic significance of neutrophil to lymphocyte ratio in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Chin Med J (Engl) 2014;127:4204–4209. doi: 10.3760/cma.j.issn.0366-6999.20141234. PubMed DOI

Kwon JH, Jang JW, Kim YW, Lee SW, Nam SW, Jaegal D, et al. The usefulness of C-reactive protein and neutrophil-to-lymphocyte ratio for predicting the outcome in hospitalized patients with liver cirrhosis. BMC Gastroenterol. 2015;15:146. doi: 10.1186/s12876-015-0378-z. PubMed DOI PMC